Telix (TLX) Q4 2025 earnings review
Hyper-Growth Top Line, But Heavy Reinvestment Pushes Bottom Line into the Red
Telix achieved a record FY25, accelerating revenue by 56% to $803.8M, driven by strong Precision Medicine sales (Illuccix/Gozellix) and the $230M acquisition of RLS Radiopharmacies. However, earnings are reversing: Net Income dropped from a $33.7M profit in FY24 to a $7.1M loss in FY25. Management explicitly stated they are prioritizing aggressive pipeline development over near-term EPS, guiding for an immense R&D spend of $200-$240M in FY26. While FDA Complete Response Letters (CRLs) for Zircaix and Pixclara delayed anticipated 2025 product launches, FY26 revenue guidance of $950M-$970M confirms the core business remains a powerful, cash-generating engine.
🐂 Bull Case
The Precision Medicine segment generated $216.4M in Adjusted EBITDA (+24% YoY). This provides a massive, non-dilutive funding source for the company's ambitious therapeutics pipeline.
The acquisitions of RLS and ARTMS secure vital U.S. distribution networks and in-house isotope production capabilities, establishing a formidable moat against emerging radiopharma competitors who rely on fragmented third-party supply chains.
🐻 Bear Case
FDA rejections for Zircaix and Pixclara highlight the inherent risks in novel radiopharma pathways. Further delays in 2026 resubmissions could stagnate growth and maintain over-reliance on the prostate cancer portfolio.
Consolidated gross margins fell from 65% to 53% due to low-margin RLS third-party sales. Coupled with management's commitment to heavy R&D spend, near-term GAAP unprofitability is virtually guaranteed.
⚖️ Verdict: ⚪
Hold. The top-line growth and strategic vertical integration are undeniably bullish, but the combination of regulatory CRLs, margin dilution, and intentional near-term unprofitability requires patience. Telix is building a 2028 therapeutics powerhouse, but 2026 will be a transition year funded by the existing diagnostics portfolio.
Key Themes
Precision Medicine Cash Engine
The Precision Medicine (Px) segment is accelerating, with revenue up 22% to $621.9M. Growth was driven by Illuccix's market share gains and the successful U.S. launch of Gozellix. This segment throws off significant cash, yielding $216.4M in Adjusted EBITDA, enabling Telix to internally fund its therapeutic clinical trials.
Vertical Integration via RLS & ARTMS
Telix's manufacturing strategy is accelerating. The $230M acquisition of RLS Radiopharmacies added 30+ US locations, fundamentally shifting Telix from relying on external CMOs to controlling its 'last-mile' delivery. Furthermore, the ARTMS acquisition integrates the QUANTM Irradiation System (QIS) cyclotron technology, derisking the supply of crucial isotopes like Gallium-68 and Zirconium-89.
Late-Stage Therapeutics Pipeline Progress
The Therapeutics pipeline is stable and progressing toward a targeted 2028 commercial launch. The flagship ProstACT GLOBAL trial for TLX591-Tx (prostate cancer) completed Part 1 target enrollment and has dosed first patients in Part 2 (randomized expansion) outside the US, with FDA submission for US inclusion pending. TLX101-Tx (glioblastoma) and TLX250-Tx (kidney cancer) have both advanced into pivotal Phase 2/3 trials.
Regulatory Stumbles Push Back Launches
A major red flag emerged as the FDA issued Complete Response Letters (CRLs) for both of Telix's highly anticipated imaging agents in 2025: Zircaix (renal cancer) and Pixclara (glioma). The Zircaix delay centers on Chemistry, Manufacturing, and Controls (CMC) deficiencies, while Pixclara requires additional confirmatory clinical evidence. While management claims alignment with the FDA for 2026 resubmissions, these delays restrict near-term revenue diversification.
RLS Acquisition Dilutes Gross Margin
While the RLS acquisition added over $170M in revenue, its third-party distribution business carries significantly lower margins than Telix's proprietary products. This mix shift caused consolidated gross margin to reverse, dropping from 65% in FY24 to 53% in FY25. Management expects this metric to recover toward 70% only once a larger share of proprietary products flows through the in-house pharmacy network.
Intentional Profitability De-prioritization
Earnings are reversing. Despite massive revenue growth, Telix swung to a $(7.1M) net loss. Management was explicit on the earnings call: they will reinvest earnings to get close to zero NPAT for 2026 and 2027. Investors seeking bottom-line GAAP profitability will be disappointed, as R&D and SG&A expenses will aggressively scale to fund the therapeutic pipeline.
Navigating CMS Reimbursement Shifts (Macro)
The U.S. reimbursement landscape for radiopharmaceuticals remains a critical macro variable. Illuccix faced headwinds in Q3 as its Transitional Pass-Through (TPT) status expired, shifting it to Mean Unit Cost (MUC) reimbursement for a subset of Medicare patients. However, the FDA approval of Gozellix in March 2025 unlocked a fresh 3-year TPT window starting October 2025. This dual-product strategy provides an economic moat against reimbursement fluctuations.
AlFluor Platform and Alpha-Therapies (Innovation)
Telix is heavily investing in next-generation radiopharmaceutical tech. The newly launched 'AlFluor' platform enables flexible radiolabeling using 18F-aluminum fluoride, offering centralized cyclotron production as an alternative to gallium-68. Additionally, Telix achieved a breakthrough in alpha-emitting isotopes, successfully producing Lead-212 (212Pb) via a novel generator technology designed for deployment across the RLS network.
Other KPIs
Reversing from +$27.5M in FY24 to a $(17.3M) outflow in FY25. However, this was heavily skewed by a final $51.8M contingent earn-out payment related to the ANMI acquisition. Adjusting for this one-time cash drag, underlying operating cash flow was a positive $34.5M, reflecting strong underlying cash generation from the Precision Medicine segment.
Accelerating. Finance costs jumped 67% YoY from $24.4M in FY24. This increase is primarily driven by the full-year impact of interest paid and the unwind of the discount on the $426M Convertible Bonds issued in July 2024 to fund aggressive M&A and capital expenditure.
Accelerating. Up 12% YoY from $85.3M. This increase was driven by the integration of 11 months of RLS operations, costs incurred to implement a Sarbanes-Oxley program for the Nasdaq listing, and professional fees connected to an SEC subpoena regarding past therapeutic disclosures.
Guidance
Decelerating in percentage terms but growing strongly in absolute dollars. The midpoint of $960M implies ~19% YoY growth from FY25's $803.8M. This guidance explicitly excludes potential revenue contributions from pending product approvals (Zircaix/Pixclara), representing potential upside if FDA approvals occur earlier in the year.
Accelerating. The midpoint of $220M implies a ~28% YoY increase from FY25's $171.2M. This massive capital allocation is directed predominantly at the late-stage therapeutics pipeline (ProstACT Global, LUTEON, IPAX-BrIGHT), confirming management's strategy to aggressively reinvest cash flow rather than optimizing for near-term net income.
Key Questions
Zircaix CRL Remediation Timeline
You mentioned the CMC deficiencies for Zircaix primarily relate to lab and process documentation, but also require bridging data between clinical and commercial scale-up material. What is the precise timeline for resubmission, and does the FDA's request for comparability data risk requiring any additional patient bridging studies?
RLS Margin Trajectory
RLS third-party sales compressed consolidated gross margins to 53%. What is the specific target mix of proprietary vs. third-party volumes flowing through the RLS network needed to return consolidated gross margins back to the historical 65-70% range?
Profitability Inflection Point
With management explicitly de-prioritizing near-term EPS to fund the $200-$240M R&D budget in FY26 and FY27, in what year does the company expect the Therapeutics portfolio to generate enough commercial revenue to structurally return the consolidated business to GAAP net income profitability?